Skip to main content
EJNMMI Research

Table 1 Demographic and clinical data of the study population

From: [18F]FE-PE2I DAT correlates with Parkinson’s disease duration, stage, and rigidity/bradykinesia scores: a PET radioligand validation study

 

Sex

Age (year) (median, range)

Symptom duration (year) (median, range)

LEDD (mg) (median, range)

(MDS-) UPDRS-III (mean ± SD) [minus tremor score]

H&Y stage (median; range)

PD Total, n = 41

12F/29M (29/71%)

67 (45–79)

3 (0.25–14)

400 (0–1010)

–

–

Subgroup 1* (’ON’)

5F/13M (28/72%)

65 (46–71)

2.5 (0.25–12)

300 (0–940)

20.44 ± 6.85 [NA]

1.5 (1–2.5)

Subgroup 2** (‘OFF’)

7F/16M (30/70%)

68 (45–79)

3 (1–14)

450 (0–1010)

21.7 ± 10.7 [17.7 ± 10.1]

1 (1–3)

HC Total, n = 37

11F/26M (30/70%)

65 (43–74)

–

–

–

–

  1. The italics are meaningful to show a difference with the first line which is the total summary data, and the two italic rows are subtotals of that one
  2. *Two were excluded compared to the published cohort (Fazio et al., 2018, n = 20): one SWEDD and one due to Freesurfer image processing error
  3. **In this subgroup, MDS-UPDRS-III was assessed in practically defined ‘OFF’
Back to article page